| Ozempic (semaglutide SC once-weekly) / Novo Nordisk |
ACTRN12621001434886: Study investigating whether the drug semaglutide could be a safe and effective way of reducing metabolic problems, such as a high Body Mass Index (BMI) and high blood sugar levels, in people with psychosis. |
|
|
| Recruiting | 4 | 100 | | | South Eastern Sydney Local Health District, Prince of Wales Hospital Foundation , SPHERE (Neuroscience, Mental Health and Addiction Clinical Academic Group), Philanthropic donation via School of Psychiatry, UNSW | Metabolic risk, Psychosis | | | | |
2019-000781-38: Effect of Empagliflozin and Semaglutide on the Cardiovascular system and Kidneys in patients with type 2 diabetes – A randomized Trial |
|
|
| Ongoing | 4 | 120 | Europe | , Tablet, Ozempic, Jardiance | Aarhus University Hospital, Novo Nordic Foundation, Aarhus University | Type 2 Diabetes Mellitus, Type 2 Diabetes, Diseases [C] - Hormonal diseases [C19] | | | | |
2019-003844-57: Comparison of injection site pain experience for semaglutide and dulaglutide sc |
|
|
| Not yet recruiting | 4 | 104 | Europe | Solution for injection, Ozempic, Trulicity | Novo Nordisk A/S, Novo Nordisk A/S | Healthy volunteers(Diabetes Mellitus, Type 2)(Overweight)(Obesity), Healthy volunteers(Type 2 diabetes)(Overweight)(Obesity), Diseases [C] - Nutritional and Metabolic Diseases [C18] | | | | |
2019-001987-31: Combined Treatment of fatty liver Inflammation and type 2 diabetes Kombinierte Behandlung der Fettleberentzündung und Typ 2 Diabetes |
|
|
| Not yet recruiting | 4 | 142 | Europe | Film-coated tablet, Solution for injection in pre-filled pen, Jardiance, Ozempic | Deutsche Diabetes Forschungsgesellschaft e.V., German Center for Diabetes Research (DZD e.V), Boehringer Ingelheim Pharma GmbH, Novo Nordisk A/S | Diabetes mellitus type 2 (T2D) and non-alcoholic steatohepatitis (NASH) Typ 2 Diabetes und nicht-alkoholische Fettleberentzündung, Type 2 Diabetes and non-alcoholic fatty liver inflammation Typ 2 Diabetes und nicht-alkoholbedingte Fettleberentzündung, Diseases [C] - Nutritional and Metabolic Diseases [C18] | | | | |
2020-000102-28: Does the glucagon-like peptide-1 receptor agonist semaglutide prevent deterioration of metabolic state in prediabetic or diabetic patients with schizophrenia treated with the antipsychotic compounds clozapine or olanzapine? Kan tillægsbehandling med glukagonlignende peptid-1 receptoragonisten semaglutid forebygge forværring af metaboliske forstyrrelser hos prediabetiske og diabtetiske skizofrene patienter, der er i behandling med olanzapin eller clozapin? |
|
|
| Not yet recruiting | 4 | 104 | Europe | Suspension for injection in pre-filled pen, Ozempic | Mental Healt Center Copenhagen, Novo Nordisk, Region Hovedstaden Psykiatri | Schizophrenia spectrum disorder F20-F29, Mental Health Psykisk sygdom, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2020-002712-51: Semaglutide in the treatment of type 2 diabetes – effects on prevention of weight regain and metabolism after diet induced weight loss Semaglutidi laihdutuksen tukena tyypin 2 diabeteksen hoidossa - vaikutukset verensokeriin, painoon ja kehon aineenvaihduntaan |
|
|
| Not yet recruiting | 4 | 75 | Europe | Solution for injection in pre-filled pen, Ozempic | Kirsi Pietiläinen, Novo Nordisk Foundation, Novo Nordisk | Type 2 diabetes Tyypin 2 diabetes, Type 2 diabetes Tyypin 2 diabetes, Diseases [C] - Nutritional and Metabolic Diseases [C18] | | | | |
2021-001661-21: Feasibility of aggressively lowering urine albumin in individuals with kidney biopsy-proven diabetic kidney disease - A Pilot Study |
|
|
| Not yet recruiting | 4 | 20 | Europe | Tablet, Injection, Forxiga, Jardiance, Ozempic, Telmisartan, Losartan, hydrochlorthiazide, Spironolactone, Trental, Olumiant, Kerendia, Rybelsus | Herlev and Gentofte Hospital, Herlev and Gentofte Hospital | Diabetic Kidney Disease, Kidney Disease due to diabetes mellitus type 2, Diseases [C] - Hormonal diseases [C19] | | | | |
| Completed | 4 | 90 | Europe | Semaglutide Pen Injector [Ozempic], Empagliflozin 10 MG | General and Teaching Hospital Celje | Endothelial Dysfunction, Diabetes Mellitus, Type 1, Biomarkers, Endothelial Progenitor Cells, SGLT 2 Inhibitors, Incretins, Glucose Excursions, FMD, FPF, Arterial Stiffness | 03/22 | 04/23 | | |
NCT03596450: Long Term Comparative Effectiveness of Once Weekly Semaglutide Versus Standard of Care in a Real World Adult US Population With Type 2 Diabetes - a Randomized Pragmatic Trial |
|
|
| Completed | 4 | 1278 | Canada, US | Semaglutide, Standard of care | Novo Nordisk A/S | Diabetes Mellitus, Type 2 | 06/22 | 06/23 | | |
| Terminated | 4 | 3 | US | Semaglutide (1 Mg Dose), semaglutide, Placebo | Geisinger Clinic, Novo Nordisk A/S | Diabetes Mellitus, Type 2 | 07/22 | 08/22 | | |
2021-006752-14: Program with Medically assisted Rapid Weight Loss as treatment of Idiopathic Intracranial Hypertension Hurtigt vægttab assisteret med medicin som behandling for idiopatisk intrkraniel hypertension |
|
|
| Not yet recruiting | 4 | 50 | Europe | Ozempic, Injection, Ozempic | Rigshospitalet, Neurologisk afdeling, Novo Nordisk Foundation | Idiopathic Intracranial Hypertension (IIH) is a disease in which the intracranial pressure is pathologically elevated. This can cause blindness, chronic, severe headache, and cognitive dysfunction. IIH is associated with obesity, and the only treatment which controls the disease is weight loss. Idiopatisk intrakraniel hypertension er en relativt sjælden tilstand, hvor væsketrykket i hjernen er forhøjet. Patienter med IIH risikerer synsstab, kronisk hovedpine og koncentrationsbesvær. IIH behandles med vægttab og vanddrivende medicin. Den eneste kendte behandling, der reelt ændrer på sygdommens aktivitet, er vægttab., Idiopathic Intracranial Hypertension (IIH) is a disease in which the brain pressure is elevated. This can cause blindness, chronic, severe headache, and cognitive dysfunction. Idiopatisk intrakraniel hypertension er en relativt sjælden tilstand, hvor væsketrykket i hjernen er forhøjet. Patienter med IIH risikerer synsstab, kronisk hovedpine og koncentrationsbesvær., Diseases [C] - Nervous System Diseases [C10] | | | | |
2019-003175-19: Effect of treatment with Empagliflozin alone or in combination with Semaglutide on protein in the urine in persons with type 2 diabetes and elevated urinary protein. Effekt af behandling med Empagliflozin og Ozempic på nyrefunktionen hos personer med type 2 diabetes og protein i urinen. |
|
|
| Not yet recruiting | 4 | 80 | Europe | Semaglutide, Empagliflozin, Solution for injection in pre-filled pen, Tablet, Ozempic, Jardiance | Steno Diabetes Center Copenhagen, Novo Nordisk A/S | Type 2 diabetes with renal complications, Type 2 diabetes with increased protein in the urine, Diseases [C] - Nutritional and Metabolic Diseases [C18] | | | | |
| Completed | 4 | 60 | US | Semaglutide, Ozempic, Insulin Degludec, Tresiba, Insulin aspart, Novolog | The Cleveland Clinic, Novo Nordisk A/S | Type 2 Diabetes | 03/23 | 11/23 | | |
ChiCTR2200058085: Clinical observation of Xiang-Sha-Liu-Jun-Zi tang (XSLJZT) for gastrointestinal side effects induced by the novel GLP-1 analogue |
|
|
| Not yet recruiting | 4 | 800 | | A dose of 0.50 mg semaglutideinjected subcutaneously (under the skin) once weekly and Xiang-Sha-Liu-Jun-Zi tang ;A dose of 0.50 mg semaglutide injected subcutaneously (under the skin) once weekly | Hospital of Chengdu University of Traditional Chinese Medicine; Hospital of Chengdu University of Traditional Chinese Medicine, Horizontal subject | Type 2 diabetes mellitus (T2DM) | | | | |
2022-003275-42: The influence of different DIets on ALECTinib exposure in lung cancer patients;the DIALECT study. |
|
|
| Ongoing | 4 | 10 | Europe | Semaglutide, Concentrate for solution for injection, Wegovy | | Weight gain is a common side effect of alectinib therapy. Semaglutide could be used as medical anti-obesity drug to prevent alectinib-induced weight gain. Since semaglutide delays gastric emptying, alectinib absorption may be influenced with a possible change in AUC. To test if semaglutide can be administered safely along with alectinib, without serious drug-drug interactions, a pharmacokinetic interaction-study is needed., To test if anti-obesity drug semaglutide can be administered safely along with alectinib, without serious interactions between the two drugs., Diseases [C] - Cancer [C04] | | | | |
NCT06475586: Effect of Semaglutide on the Psoriatic Lesions in Patients With Type 2 Diabetes Mellitus |
|
|
| Completed | 4 | 30 | RoW | Semaglutide, ozempic | University of Banja Luka | Psoriasis Vulgaris, Diabetes Type 2 | 03/24 | 06/24 | | |
| Recruiting | 4 | 45 | Europe | Semaglutide Pen Injector [Ozempic], Very-low Calorie Diet | University of Nottingham, Medical Research Council | Type 2 Diabetes Mellitus in Obese | 07/23 | 07/23 | | |
| Active, not recruiting | 4 | 16 | US | Semaglutide Pen Injector, Ozempic | State University of New York at Buffalo, National Center for Advancing Translational Sciences (NCATS) | Obesity, Aging | 10/23 | 11/24 | | |
| Active, not recruiting | 4 | 192 | Europe | Empagliflozin 10mg oral tablet / Semaglutide 1mg pen injector, Jardiance(R), Ozempic(R), Empagliflozin 10mg oral tablet and placebo pen injector matching semaglutide, Jardiance(R), Placebo matching empagliflozin and placebo pen injector matching semaglutide, Control / Placebo | German Diabetes Center, Boehringer Ingelheim, German Center for Diabetes Research, Federal Ministry of Health, Germany, Ministry of Innovation, Science and Research in North Rhine-Westphalia, Novo Nordisk A/S | Type 2 Diabetes, Non-alcoholic Steatohepatitis (NASH), Non-alcoholic Fatty Liver Disease (NAFLD) | 01/25 | 12/25 | | |
NCT05533632: Safety Study of Weekly Semaglutide in Chilean Participants With Type 2 Diabetes |
|
|
| Completed | 4 | 100 | RoW | Semaglutide | Novo Nordisk A/S | Diabetes Mellitus, Type 2 | 01/24 | 01/24 | | |
SIB, NCT04979130: Comparing Semaglutide Versus Placebo on Intestinal Barrier Function in Type 2 Diabetes Mellitus |
|
|
| Recruiting | 4 | 42 | US | Semaglutide, Ozempic, PDS290 pen-injector, Placebo | University of Colorado, Denver, Novo Nordisk A/S | Type 2 Diabetes, Chronic Inflammation, Intestinal Permeability | 12/23 | 12/23 | | |
SEMA, NCT05303857: Analyse the Effect of Semaglutide on Vascular Structure and Function in Patients With Early Type 2 Diabetes |
|
|
| Active, not recruiting | 4 | 90 | Europe | Semaglutide Pen Injector, Placebo | University of Erlangen-Nürnberg Medical School | Diabetes Mellitus, Type 2 | 12/23 | 12/24 | | |
NCT05786521: Effect of GLP1 Receptor Agonists on Physical Function, Body Composition, and Markers of Aging in Older Adults |
|
|
| Active, not recruiting | 4 | 20 | US | Semaglutide Injectable Product, Semaglutide and Lifestyle Counseling, Lifestyle Counseling | The University of Texas Health Science Center at San Antonio, National Institute on Aging (NIA) | Aging, Diabetes Mellitus, Type 2, PreDiabetes, Overweight and Obesity | 05/24 | 01/25 | | |
NCT04873050: Treatment to Regress to Normoglycemia in Women With a Recent History of GDM |
|
|
| Recruiting | 4 | 102 | US | Semaglutide Pen Injector [Ozempic], Semaglutide 1mg, Ozempic, Placebo semaglutide pen injector, Placebo Semaglutide 1mg, Placebo Ozempic | Woman's, Novo Nordisk A/S | Pre Diabetes, Postpartum Disorder | 05/25 | 08/25 | | |
NCT05813249: Semaglutide in Nonalcoholic Fatty Liver Disease |
|
|
| Completed | 4 | 180 | RoW | Rybelsus Oral Product, Ozempic Injectable Product, Wegovy, Tocopherol and/or Actos | Zagazig University | Non-alcoholic Fatty Liver Disease | 02/24 | 04/24 | | |
DOTAFLAME, NCT05597202: Does the Hematopoietic Stem Cell Govern Residual Inflammatory Cardiovascular Risk in Type 2 Diabetes |
|
|
| Recruiting | 4 | 22 | Europe | Semaglutide, 2.0 mg/mL | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), Dutch Heart Foundation | Type 2 Diabetes | 03/24 | 04/24 | | |
GLUMINS, NCT06324461: GLP-1 Receptor Agonist for Reduction of Myocardial Injury After Non-cardiac Surgery |
|
|
| Recruiting | 4 | 372 | RoW | Dulaglutide 0.75mg subcutaneous injection, Trulicity 0.75mg subcutaneous injection | The University of Hong Kong, Research Grants Council, Hong Kong | Myocardial Injury | 12/26 | 12/27 | | |
| Not yet recruiting | 4 | 152 | NA | Placebo, Semaglutide 2.4 MG/0.75 ML Subcutaneous Solution [WEGOVY], Wegovy, Semaglutide | Zuyderland Medisch Centrum, Nederlandse Obestias Kliniek (NOK) | Obesity, Obesity, Morbid, Weight Gain | 02/26 | 09/26 | | |
NCT06468748: The Effects of Semaglutide on Body Composition and Performance in Military Personnel |
|
|
| Not yet recruiting | 4 | 144 | NA | Semaglutide | United States Army Research Institute of Environmental Medicine | Obesity | 09/26 | 09/28 | | |
NCT05702905: Semaglutide Improves Metabolic Abnormalities and Fertility in Obese Infertile Women With Polycystic Ovary Syndrome |
|
|
| Recruiting | 4 | 75 | RoW | Metformin Hydrochloride 500 MG, Glucophage, Semaglutide, 1.34 mg/mL, WEGOVY, Semaglutide, 1.34 mg/mL and Metformin Hydrochloride 500 MG, WEGOVY and Glucophage, calorie-restricted diet, physical exercise | Peking University First Hospital | PCOS (Polycystic Ovary Syndrome), Semaglutide | 12/24 | 06/25 | | |
NCT04892199: Does GLP-1RA Prevent Deterioration of Metabolic State in Prediabetic and Diabetic Patients Treated With Antipsychotic Medication? |
|
|
| Active, not recruiting | 4 | 104 | Europe | Semaglutide, 1.34 mg/mL, Semaglutide-placebo | Anders Fink-Jensen, MD, DMSci | Metabolic Disturbance, Schizophrenia, Type 2 Diabetes, Clozapine, GLP-1, Olanzapine | 03/26 | 08/26 | | |
NCT06449235: Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh |
|
|
| Not yet recruiting | 4 | 938 | RoW | Omarigliptin, Sulphonylureas, Metformin, Other DPP4-i, Thiazolidinediones, Alpha-Glucosidase Inhibitor, Glucagon-Like Peptide-1, Receptor Agonists (GLP1RA), SGLT2 inhibitors | Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders, Pi Research and Development Center, Acme Laboratories Ltd. | Type2diabetes | 04/25 | 06/25 | | |
NCT06571383: STEP TEENS Weight Maintenance: A Research Study on How Well Semaglutide Helps Teenagers With Excess Body Weight to Lose Weight and Maintain Weight Loss |
|
|
| Recruiting | 4 | 500 | Europe, Canada, US, RoW | Semaglutide | Novo Nordisk A/S | Obesity | 11/28 | 11/31 | | |
| Recruiting | 4 | 60 | Canada | Semaglutide, GLP-1RA, Ozempic, Wegovy, Virtual Weight Management Coaching | Western University, Canada, Lawson Health Research Institute, Queen Elizabeth II Health Sciences Centre, St. Michael's Hospital (Toronto, Canada) | Obesity, Chronic Kidney Disease | 12/25 | 12/25 | | |
| Recruiting | 4 | 180 | NA | TCOC treatment, Semaglutide 3 mg | Signe Torekov, University of Leeds, Karolinska Institutet, Holbaek Sygehus, Rigshospitalet, Denmark | Obesity, Adolescent | 10/25 | 04/26 | | |
NCT05579249: A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America |
|
|
| Completed | 4 | 500 | US | Semaglutide, Wegovy, Orlistat, Xenical, Phentermine/Topiramate, Qsymia, Naltrexone/Bupropion, Contrave, Liraglutide, Saxenda | Novo Nordisk A/S | Obesity | 11/24 | 11/24 | | |
| Recruiting | 4 | 100 | Canada | Semaglutide Pen Injector, Ozempic, Wegovy | Canadian Medical and Surgical Knowledge Translation Research Group, Unity Health Toronto, Western University, Canada | Atherosclerosis, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Obesity | 12/24 | 12/24 | | |
STEP@STAH, NCT06754163: Evaluating the Effect of the Semaglutide Protocol on the Physical Health Measures of Atypical Antipsychotic-Treated Patients |
|
|
| Recruiting | 4 | 20 | Europe | Semaglutide in combination with a healthy lifestyle intervention (diet and exercise) | St Andrew's Healthcare, Loughborough University | Obesity and Obesity-related Medical Conditions, Psychiatric Disorders | 12/26 | 06/27 | | |
NCT06706284: Glycemic and Weight Loss Effects of GLP-1R Agonist Therapy in Subjects With Spinal Cord Injury and Type 2 Diabetes |
|
|
| Recruiting | 4 | 50 | US | Semaglutide Injectable Product, Ozempic, Placebo, Saline solution | Marzieh Salehi, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Spinal Cord Injuries, Type 2 Diabetes | 05/28 | 01/29 | | |
NCT06803888: Bariatric Surgery Vs. Semaglutide Vs. Tirzepatide |
|
|
| Not yet recruiting | 4 | 125 | US | Bariatric Surgery, Metabolic Surgery, Roux-en-Y Gastric Bypass (RYGB), Sleeve Gastrectomy (SG), Semaglutide, Ozempic, Wegovy, Tirzepatide, Mounjaro, Zepbound | Ali Aminian, Ethicon, Inc. | Obesity and Obesity-related Medical Conditions | 07/27 | 12/27 | | |
IIH:DUAL, NCT06027567: The Effect of an Anti-obesity Drug, Semaglutide, As Treatment in New-onset Idiopathic Intracranial Hypertension (IIH) Compared to Standard Weight Management (dietician) with Regards to Change in Weight and Intracranial Pressure |
|
|
| Active, not recruiting | 4 | 50 | Europe | Semaglutide, Ozempic, Wegovy, Very Low Calorie Diet, Dietician counselling | Rigmor Højland Jensen, Rigshospitalet, Denmark, Odense University Hospital, University of Copenhagen | Idiopathic Intracranial Hypertension, Intracranial Pressure, Obesity, Pseudotumor Cerebri Syndrome, Papilledema, Weight Loss | 01/25 | 10/25 | | |
| Active, not recruiting | 4 | 120 | US | Behavioral Treatment, Lifestyle modification, Behavioral weight loss, Lifestyle intervention, Placebo, Placebo for medication, Semaglutide 2.4 MG/0.75 ML Subcutaneous Solution [WEGOVY], Wegovy | University of Pennsylvania, Novo Nordisk A/S | Obesity | 07/25 | 07/25 | | |
| Recruiting | 4 | 50 | Europe | Semaglutide, 1.34 mg/mL, Ozempic, Placebo | Kirsi Pietiläinen, University of Helsinki, Turku University Hospital | Type2 Diabetes | 08/25 | 08/25 | | |
NCT05119179: Pharmacogenetics of the Response to GLP-1 in Mexican-Americans With Prediabetes |
|
|
| Recruiting | 4 | 300 | US | Semaglutide, Ozempic | The University of Texas Health Science Center, Houston, Vanderbilt University Medical Center, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | PreDiabetes | 11/25 | 07/26 | | |
NCT05780905: Effects of Semaglutide on Intracranial Blood Flow and Brain-Barrier Permeability in Type-2 Diabetes |
|
|
| Recruiting | 4 | 50 | US | Semaglutide Auto-Injector, ozempic, Placebo | University of Washington, Novo Nordisk A/S | Diabetes Mellitus, Type 2, Stroke (CVA) or Transient Ischemic Attack | 03/26 | 12/26 | | |
2018-004422-29: A phase 3 study comparing the safety and efficacy of the drug tirzepatide versus the drug semaglutide as additional therapy to the drug metformin in patients with type 2 diabetes. |
|
|
| Not yet recruiting | 3 | 1872 | Europe | Tirzepatide, Ozempic, LY3298176, Solution for injection in pre-filled pen, Ozempic | Eli Lilly and Company, Eli Lilly and Company | Type 2 diabetes mellitus, Type 2 Diabetes mellitus, Diseases [C] - Hormonal diseases [C19] | | | | |
2018-004120-11: Triple Therapy for Type 1 Diabetes with Insulin, Semaglutide and Dapagliflozin. |
|
|
| Ongoing | 3 | 114 | Europe | Ozempic, Forxiga, Not applicable, Solution for injection in pre-filled pen, Capsule, Ozempic, Forxiga | NHS Greater Glasgow and Clyde, University of Glasgow, , JDRF | Type 1 diabetes, Type 1 diabetes, Diseases [C] - Hormonal diseases [C19] | | | | |
2019-003399-38: A research study to compare a medicine called semaglutide against placebo in people with peripheral arterial disease and type 2 diabetes |
|
|
| Not yet recruiting | 3 | 800 | Europe | Solution for injection, Ozempic® | Novo Nordisk A/S, Novo Nordisk A/S | Peripheral arterial diseaseDiabetes Mellitus, Type 2, Peripheral arterial diseaseType 2 diabetes, Diseases [C] - Nutritional and Metabolic Diseases [C18] | | | | |
SEMAT, NCT06489457: The Effects of Semaglutide vs Testosterone Replacement Therapy on Functional Hypogonadism and Sperm Quality in Men With Type 2 Diabetes Mellitus and Obesity |
|
|
| Completed | 3 | 25 | Europe | Semaglutide, Testosterone Undecanoate | University Medical Centre Ljubljana | Type 2 Diabetes Mellitus, Obesity, Functional Hypogonadism | 05/23 | 06/23 | | |
2020-000204-11: Research study looking at how well semaglutide works in people suffering from obesity and knee osteoarthritis Etude clinique évaluant l’efficacité du semaglutide chez des patients atteints d’obésité et d’arthrose du genou |
|
|
| Ongoing | 3 | 375 | Europe | Semaglutide B 3.0 mg/mL PDS290, Solution for injection | Novo Nordisk A/S, Novo Nordisk A/S | Obesity, Obesity, Diseases [C] - Nutritional and Metabolic Diseases [C18] | | | | |
2020-002939-29: Research study looking at how well semaglutide works in people living with obesity and prediabetes |
|
|
| Ongoing | 3 | 201 | Europe | Semaglutide D 0.5 mg/mL DV3396, Semaglutide D 1.0 mg/mL DV3396, Semaglutide D 2.0 mg/mL DV3396, Semaglutide D 2.27 mg/mL DV3396, Semaglutide D 3.2 mg/mL DV3396, Solution for injection | Novo Nordisk A/S, Novo Nordisk A/S | Obesity, Obesity, Diseases [C] - Nutritional and Metabolic Diseases [C18] | | | | |
2021-003880-88: Effet d'un traitement par agoniste GLP1 hebdomadaire dans le "diabète double" |
|
|
| Not yet recruiting | 3 | 76 | Europe | Solution for injection in pre-filled pen, Ozempic® | CHU Dijon Bourgogne | Diabète double, Diabète double | | | | |
2020-005308-21: A research study to see how well the new weekly medicine IcoSema, which is a combination of insulin icodec and semaglutide, controls blood sugar level in people with type 2 diabetes compared to weekly semaglutide (COMBINE 2) COMBINE 2 – Klinické skúšanie, ktoré skúma ako dobre nový liek IcoSema, ktorý je kombináciou inzulínu icodec a semaglutidu, kontroluje hladinu cukru v krvi u ľudí s cukrovkou 2. typu, a porovnáva ho s liekom semaglutid, oba podávané raz týždenne |
|
|
| Ongoing | 3 | 680 | Europe | IcoSema 700 U/ml + 2 mg/mL PDS290, Solution for injection, Solution for injection in pre-filled pen, Ozempic | Novo Nordisk A/S, Novo Nordisk A/S | Diabetes Mellitus, Type 2, Type 2 diabetes, Diseases [C] - Nutritional and Metabolic Diseases [C18] | | | | |
2021-004392-13: A research study to look into how well semaglutide, together with insulin glargine, compares to a higher dose of insulin glargine alone in people with type 2 diabetes SUSTAIN OPTIMIZE - Klinické skúšanie, ktoré skúma ako účinkuje semaglutid pridaný k zníženej dávke inzulínu glargínu a porovnáva ho so samotným inzulínom glargínom vo vyššej dávke u ľudí s cukrovkou 2. typu |
|
|
| Ongoing | 3 | 568 | Europe | Semaglutide B 2.68 mg/ml PDS290, [Semaglutide], [N/A], Solution for injection, Lantus SoloStar, Ozempic | Novo Nordisk A/S, NOVO NORDISK. S.P.A., Novo Nordisk A/S | Diabetes Mellitus, type 2, Type 2 diabetes, Diseases [C] - Nutritional and Metabolic Diseases [C18] | | | | |
NCT04447859: 16-week Flexible vs. 8-week Semaglutide Titration |
|
|
| Recruiting | 3 | 100 | RoW | Semaglutide, Ozempic, label recommended titration | Tel-Aviv Sourasky Medical Center | Diabetes type2 | 05/22 | 09/22 | | |
2020-005435-75: REDEFINE 1: A research study to see how well CagriSema helps people losing weight in people who have a body weight above the healthy range |
|
|
| Ongoing | 3 | 3400 | Europe | Cagrilintide B 1.0 mg/mL + semaglutide I 0.5 mg/mL DV3384, Cagrilintide B 1.0 mg/mL / placebo DV3384, Cagrilintide B 2.0 mg/mL + semaglutide I 1.0 mg/mL DV3384, Cagrilintide B 4.0 mg/mL + semaglutide I 2.0 mg/mL DV3384, Cagrilintide B 6.8 mg/mL + semaglutide I 3.4 mg/mL DV3384, Cagrilintide B 9.6 mg/mL + semaglutide I 4.8 mg/mL DV3384, Cagrilintide B 2.0 mg/mL / placebo DV3384, Cagrilintide B 4.0 mg/mL / placebo DV3384, Cagrilintide B 6.8 mg/mL / placebo DV3384, Cagrilintide B 9.6 mg/mL / placebo DV3384, Solution for injection in pre-filled pen, Wegovy | Novo Nordisk A/S, Novo Nordisk A/S | Obesity, Overweight, Obesity, Overweight, Diseases [C] - Nutritional and Metabolic Diseases [C18] | | | | |
2021-001501-69: A Research Study to Compare Two Semaglutide Medicines in People with Type 2 Diabetes Klinické skúšanie, ktoré porovnáva dva skúšané lieky semaglutid u ľudí s cukrovkou 2. typu |
|
|
| Not yet recruiting | 3 | 380 | Europe | Semaglutide J 1.34 mg/mL, Solution for injection, Ozempic | Novo Nordisk A/S, Novo Nordisk A/S | Diabetes mellitus, Type 2, Type 2 diabetes, Diseases [C] - Nutritional and Metabolic Diseases [C18] | | | | |
2021-005121-24: A research study to see how well CagriSema helps people losing weight in people who have a body weight above the healthy range and type 2 diabetes Klinikai vizsgálat annak megállapítására, mennyire segíti a CagriSema a fogyást az egészséges tartomány feletti testsúlyú, 2-es típusú cukorbetegeknél |
|
|
| Ongoing | 3 | 1200 | Europe | Cagrilintide B 1.0 mg/mL + semaglutide I 0.5 mg/mL DV3384, Cagrilintide B 2.0 mg/mL + semaglutide I 1.0 mg/mL DV3384, Cagrilintide B 4.0 mg/mL + semaglutide I 2.0 mg/mL DV3384, Cagrilintide B 6.8 mg/mL + semaglutide I 3.4 mg/mL DV3384, Cagrilintide B 9.6 mg/mL + semaglutide I 4.8 mg/mL DV3384, Solution for injection in pre-filled pen | Novo Nordisk A/S, Novo Nordisk A/S | Overweight, Obesity and Diabetes Mellitus, Type 2 Túlsúly, obezitás és 2-es típusú diabétesz mellitus, Overweight, Obesity and Type 2 diabetes Túlsúly, obezitás és 2-es típusú diabétesz mellitus, Diseases [C] - Nutritional and Metabolic Diseases [C18] | | | | |
2022-000790-94: A research study to see how semaglutide helps losing weight in people with excess weight (STEP UP). |
|
|
| Ongoing | 3 | 1450 | Europe, RoW | Solution for injection in pre-filled pen, Wegovy 0.25 mg solution for injection in pre-filled pen, Wegovy 0.5 mg solution for injection in pre-filled pen, Wegovy 1.0 mg solution for injection in pre-filled pen, Wegovy 1.7 mg solution for injection in pre-filled pen, Wegovy 2.4 mg solution for injection in pre-filled pen | Novo Nordisk A/S, Novo Nordisk A/S | Obesity, Body weight above the healthy range, Diseases [C] - Nutritional and Metabolic Diseases [C18] | | | | |
2022-002235-60: A research study to see how semaglutide helps losing weight in people with excess weight and type 2 diabetes Klinické skúšanie, ktoré sleduje ako semaglutid pomáha chudnúť ľuďom s nadváhou a cukrovkou 2. typu |
|
|
| Ongoing | 3 | 520 | Europe, RoW | Solution for injection in pre-filled pen, Wegovy 0.25 mg solution for injection in pre-filled pen, Wegovy 0.5 mg solution for injection in pre-filled pen, Wegovy 1.0 mg solution for injection in pre-filled pen, Wegovy 1.7 mg solution for injection in pre-filled pen, Wegovy 2.4 mg solution for injection in pre-filled pen | Novo Nordisk A/S, Novo Nordisk A/S | Obesity, Body weight above the healthy range, Diseases [C] - Nutritional and Metabolic Diseases [C18] | | | | |
| Completed | 3 | 207 | Europe, Canada | Semaglutide 2.4 mg, Placebo | Novo Nordisk A/S, Novo Nordisk A/S | Obesity | 01/23 | 07/23 | | |
2021-005855-35: A research study to see the effects of CagriSema on heart disease in people living with obesity and diseases in the heart and blood vessels |
|
|
| Ongoing | 3 | 4000 | Europe | Cagrilintide B 1.0 mg/ml + semaglutide I 0.5 mg/ml DV3384, Cagrilintide B 2.0 mg/ml + semaglutide I 1.0 mg/ml DV3384, Cagrilintide B 4.0 mg/ml + semaglutide I 2.0 mg/ml DV3384, Cagrilintide B 6.8 mg/ml + semaglutide I 3.4 mg/ml DV3384, Cagrilintide B 9.6 mg/ml + semaglutide I 4.8 mg/ml DV3384, Solution for injection in pre-filled pen | Novo Nordisk A/S, Novo Nordisk A/S | Atherosclerotic cardiovascular disease and Obesity, Cardiovascular disease and Body weight above the healthy range, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
2022-003384-24: A research study looking at the effect of semaglutide on the immune system and other biological processes in people with Alzheimer’s disease |
|
|
| Ongoing | 3 | 24 | Europe | Solution for injection, Ozempic® | Novo Nordisk A/S, Novo Nordisk A/S | Mild cognitive impairment (MCI) or mild dementia, both of the Alzheimer’s type, Early Alzheimer's disease, Diseases [C] - Nervous System Diseases [C10] | | | | |
| Completed | 3 | 529 | Europe, Canada, US, RoW | Semaglutide, Placebo (semaglutide) | Novo Nordisk A/S | Obesity | 04/23 | 04/23 | | |
| Completed | 3 | 407 | Europe, Canada, US, RoW | semaglutide 2.4 mg, semaglutide 2.4 mg (placebo) | Novo Nordisk A/S, Novo Nordisk A/S | Obesity | 07/23 | 09/23 | | |
| Completed | 3 | 388 | Europe, Canada, US, RoW | Semaglutide J, Semaglutide B | Novo Nordisk A/S, Novo Nordisk A/S | Diabetes Mellitus, Type 2 | 08/23 | 09/23 | | |
NCT06739044: Efficacy and Safety of Semaglutide Injection Vs Ozempic® in Patients with Type 2 Diabetes |
|
|
| Active, not recruiting | 3 | 494 | RoW | Ozempic®, HDG1901 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Type 2 Diabetes | 10/24 | 02/25 | | |
| Completed | 3 | 617 | Europe, Canada, Japan, US, RoW | Semaglutide, Placebo (Semaglutide) | Novo Nordisk A/S | Heart Failure With Preserved Ejection Fraction (HFpEF) and Diabetes Mellitus, Type 2 | 10/23 | 10/23 | | |
NCT04998136: Research Study Investigating How Well Semaglutide Works in People From Thailand and South Korea Living With Obesity |
|
|
| Completed | 3 | 151 | RoW | Semaglutide 2.4 mg, Placebo (semaglutide 2.4 mg) | Novo Nordisk A/S | Obesity | 10/23 | 11/23 | | |
NCT06131437: A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight |
|
|
| Active, not recruiting | 3 | 800 | US | Cagrilintide, Semaglutide, Tirzepatide | Novo Nordisk A/S | Obesity | 08/25 | 10/25 | | |
COMBINE 2, NCT05259033 / 2020-005308-21: A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Semaglutide |
|
|
| Completed | 3 | 683 | Europe, Canada, Japan, US, RoW | IcoSema, Semaglutide 1 mg | Novo Nordisk A/S, Novo Nordisk A/S | Diabetes Mellitus, Type 2 | 12/23 | 01/24 | | |
NCT05816057: A Study of the Efficacy and Safety of Semaglutide Injection in the Treatment of Type 2 Diabetes Mellitus |
|
|
| Completed | 3 | 476 | RoW | semaglutide injection | Hangzhou Jiuyuan Gene Engineering Co. Ltd., | Diabetes Mellitus, Type 2 | 07/23 | 10/23 | | |
| Withdrawn | 3 | 100 | NA | Semaglutide Injectable Product, Semaglutide plus lifestyle and cardiovascular risk factor management, Placebo, Lifestyle and risk factor management alone | Axel Brandes, Herlev and Gentofte Hospital, Hillerod Hospital, Denmark, Svendborg Hospital, Hospital of South West Jutland | Atrial Fibrillation, Overweight and Obesity | 01/24 | 11/24 | | |
NN9388-4894, NCT06221969: A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor |
|
|
| Active, not recruiting | 3 | 1000 | Canada, US, RoW | Cagrilintide, Semaglutide, Tirzepatide | Novo Nordisk A/S | Type 2 Diabetes | 03/26 | 04/26 | | |
TRANSCEND-T2D-2, NCT06260722: Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor |
|
|
| Recruiting | 3 | 1250 | Canada, US, RoW | Retatrutide, LY3437943, Semaglutide | Eli Lilly and Company | Diabetes Mellitus, Type 2 | 12/26 | 03/27 | | |
NCT06161844: Efficacy and Safety of Semaglutide Injection (HD1916) in Patients with Type 2 Diabetes Mellitus |
|
|
| Recruiting | 3 | 506 | RoW | semaglutide injection (HD1916), Ozempic® | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Type 2 Diabetes Mellitus | 08/25 | 02/26 | | |
DREAMS-3, NCT06184568: A Study Comparing IBI362 vs Semaglutide in Chinese Adults With Early Type 2 Diabetes and Obesity |
|
|
| Active, not recruiting | 3 | 349 | RoW | IBI362, Semaglutide | Innovent Biologics (Suzhou) Co. Ltd. | Type 2 Diabetes, Obesity | 02/26 | 06/26 | | |
| Completed | 3 | 125 | Europe, Canada | Semaglutide, Placebo | University Medical Center Groningen, Novo Nordisk A/S | Obesity, Albuminuria | 05/24 | 05/24 | | |
REIMAGINE 1, NCT06323174: A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise |
|
|
| Active, not recruiting | 3 | 180 | Europe, US, RoW | Cagrilintide, Semaglutide, Placebo | Novo Nordisk A/S | Type 2 Diabetes | 10/25 | 12/25 | | |
REIMAGINE 3, NCT06323161: A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Once-daily Basal Insulin With or Without Metformin |
|
|
| Active, not recruiting | 3 | 270 | Europe, Japan, US, RoW | Cagrilintide, Semaglutide, Placebo | Novo Nordisk A/S | Type 2 Diabetes | 09/25 | 11/25 | | |
NCT06339086: Efficacy and Safety of Semaglutide Injection in Subjects With Type 2 Diabetes |
|
|
| Not yet recruiting | 3 | 478 | NA | Semaglutide Injection, Semaglutide Injection(Ozempic®), Ozempic®, Metformin, Glucophage® | Chengdu Brilliant Pharmaceutical Co., Ltd. | Type 2 Diabetes Mellitus | 08/25 | 12/25 | | |
| Completed | 3 | 119 | US | Semaglutide 2.4mg, Placebo | Loma Linda University, Novo Nordisk A/S | Obesity, Obesity; Drug, Overweight or Obesity, Weight Loss, Weight Loss Trajectory, Weight, Body | 05/24 | 05/24 | | |
NCT06361823: Exploratory Study on the Efficacy and Safety of Semaglutide for Idiopathic Intracranial Hypertension Treatment |
|
|
| Not yet recruiting | 3 | 74 | NA | Semaglutide, Ozempic, Low calorie diet | Capital Medical University | Idiopathic Intracranial Hypertension | 12/24 | 01/25 | | |
NCT05891496 / 2022-003384-24: A Research Study Looking at the Effect of Semaglutide on the Immune System and Other Biological Processes in People With Alzheimer's Disease |
|
|
| Active, not recruiting | 3 | 24 | Europe, Canada, US | Semaglutide, Placebo | Novo Nordisk A/S, Novo Nordisk A/S | Alzheimers Disease | 08/24 | 09/25 | | |
STRIDE, NCT04560998: A Research Study to Compare a Medicine Called Semaglutide Against Placebo in People With Peripheral Arterial Disease and Type 2 Diabetes |
|
|
| Completed | 3 | 792 | Europe, Canada, Japan, US, RoW | Semaglutide, Placebo (semaglutide) | Novo Nordisk A/S | Diabetes Mellitus, Type 2, Peripheral Arterial Disease | 06/24 | 07/24 | | |
NCT06388187: A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose Weight |
|
|
| Active, not recruiting | 3 | 300 | Europe, Canada, US | Cagrilintide, Semaglutide, Placebo | Novo Nordisk A/S | Obesity | 02/26 | 04/26 | | |
NCT05813912: A Research Study to See How a New Weekly Insulin, Insulin Icodec When Given Along With Semaglutide Helps in Reducing the Blood Sugar Level in Patients With Type 2 Diabetes |
|
|
| Recruiting | 3 | 148 | Europe, RoW | Insulin Icodec, Semaglutide | Novo Nordisk A/S | Diabetes Mellitus, Type 2 | 09/24 | 07/25 | | |
| Completed | 3 | 1407 | Europe, Canada, US, RoW | Semaglutide, Placebo | Novo Nordisk A/S, Novo Nordisk A/S | Obesity | 10/24 | 11/24 | | |
| Active, not recruiting | 3 | 462 | RoW | HD1916, semaglutide | CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. | Weight Management | 02/26 | 03/26 | | |
| Completed | 3 | 513 | Europe, Canada, US, RoW | Semaglutide, Placebo | Novo Nordisk A/S, Novo Nordisk A/S | Obesity, Diabetes Mellitus, Type 2 | 10/24 | 12/24 | | |
REMODEL, NCT04865770 / 2020-000828-19: A Research Study to Find Out How Semaglutide Works in the Kidneys Compared to Placebo, in People With Type 2 Diabetes and Chronic Kidney Disease (the Trial) |
|
|
| Completed | 3 | 106 | Europe, Canada, US, RoW | Semaglutide, Placebo (Semaglutide) | Novo Nordisk A/S | Diabetes Mellitus, Type 2, Chronic Kidney Disease | 11/24 | 11/24 | | |
| Active, not recruiting | 3 | 3400 | Europe, Canada, Japan, US, RoW | Cagrilintide, Semaglutide, Placebo cagrilintide, Placebo semaglutide | Novo Nordisk A/S, Novo Nordisk A/S | Obesity | 10/24 | 10/26 | | |
NCT06633783: A Phase III Study Comparing the Weight Loss Effects of Semaglutide Injection and Wegovy® |
|
|
| Not yet recruiting | 3 | 370 | RoW | Semaglutide | Hangzhou Jiuyuan Gene Engineering Co. Ltd., | Obesity | 05/26 | 10/26 | | |
NCT06649344: A Study of HRS9531 Versus Semaglutide Once Weekly as Add-on Therapy to Metformin Monotherapy or in Combination With SGLT2 Inhibitors in Participants With Type 2 Diabetes |
|
|
| Recruiting | 3 | 840 | RoW | HRS9531 Injection, Semaglutide Injection | Fujian Shengdi Pharmaceutical Co., Ltd. | Type 2 Diabetes | 09/26 | 09/26 | | |
NCT06616961: Efficacy and Safety of Semaglutide for Weight Loss in Overweight or Obese Adults in Bangladesh With or Without Type 2 Diabetes Mellitus |
|
|
| Not yet recruiting | 3 | 480 | RoW | Semaglutide Pen, Semaglutide Pen without ADA | Popular Medical College Hospital, Pi Research and Development Center, Bangladesh, Incepta Pharmaceuticals Ltd | Obesity, Type 2 Diabetes Mellitus (T2DM) | 02/25 | 10/26 | | |
REIMAGINE 5, NCT06534411: A Research Study to See How Much CagriSema (1.0 mg Once Weekly) Lowers Blood Sugar and Body Weight Compared to Tirzepatide (5 mg Once Weekly) in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both |
|
|
| Recruiting | 3 | 1000 | Europe, Canada, US, RoW | Cagrilintide, Semaglutide, Tirzepatide | Novo Nordisk A/S | Diabetes Mellitus, Type 2 | 07/26 | 08/26 | | |
NCT05950516: Efficacy and Safety of Semaglutide Ingection in Subjects With Type 2 Diabetes |
|
|
| Not yet recruiting | 3 | 478 | RoW | Semaglutide, QLG2065, Semaglutide Pen Injector [Ozempic], Ozempic Injectable Product | Qilu Pharmaceutical Co., Ltd. | Type 2 Diabetes | 11/24 | 01/25 | | |
| Not yet recruiting | 3 | 120 | NA | Semaglutide | Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León | Atheroscleroses, Coronary | 12/24 | 12/25 | | |
NCT06716216: A Study of BGM0504 in Participants With Type 2 Diabetes |
|
|
| Recruiting | 3 | 537 | RoW | Drug: 5 mg BGM0504 Administered SC, Drug:10 mg BGM0504 Administered SC, Drug: Semaglutide Administered SC | BrightGene Bio-Medical Technology Co., Ltd., BrightGene New Bio-Medical Technology(Wuxi) Co.Ltd. | Type 2 Diabetes Mellitus (T2DM) | 03/26 | 11/26 | | |
| Active, not recruiting | 3 | 1200 | Europe, Canada, Japan, US, RoW | Cagrilintide, Semaglutide, Placebo cagrilintide, Placebo semaglutide | Novo Nordisk A/S, Novo Nordisk A/S | Overweight, Obesity, Type 2 Diabetes Mellitus | 12/24 | 01/25 | | |
